NCT01957007View on ClinicalTrials.gov

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2017

Conditions
Solid Tumors
Interventions
DRUG

Docetaxel

Docetaxel will be administered IV.

DRUG

vantictumab

Vantictumab will be administered intravenously

Trial Locations (3)

14263

Roswell Park Cancer Center, Elm & Carlton Streets, Buffalo

44106

Case Western Reserve University, Cleveland

80045

University of Colorado, Aurora

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT01957007 - A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | Biotech Hunter | Biotech Hunter